STOCK TITAN

Synlogic - SYBX STOCK NEWS

Welcome to our dedicated page for Synlogic news (Ticker: SYBX), a resource for investors and traders seeking the latest updates and insights on Synlogic stock.

Overview of Synlogic

Synlogic Inc is a pioneering biopharmaceutical company dedicated to developing transformative therapies through the innovative convergence of synthetic biology and microbiome science. Leveraging its proprietary synthetic biotics platform, Synlogic engineers probiotic bacteria to carry out specific therapeutic functions that address rare metabolic disorders and other serious diseases. Utilizing concepts from synthetic biology, the company focuses on the design and development of engineered probiotics that are formulated to be administered orally, targeting the gut microbiome in order to rectify missing or malfunctioning metabolic activities.

Core Business and Therapeutic Approach

At its core, Synlogic is engaged in the discovery and development of innovative drug candidates known as synthetic biotics. These therapeutic agents are created by applying precision genetic engineering to a well-characterized strain of Escherichia coli, ensuring consistency and safety in their deployment. The company’s drug candidates are designed to be non-colonizing and reversible, emphasizing a safety profile that simplifies shipping, storage, and clinical administration.

The therapeutic paradigm adopted by Synlogic involves targeting specific biological pathways implicated in rare metabolic diseases. Synlogic’s lead programs focus on conditions such as phenylketonuria (PKU), homocystinuria (HCU), and other rare genetic disorders where metabolic functions are compromised. By introducing engineered microbes into the gastrointestinal tract, the company seeks to correct metabolic deficiencies and, in certain cases, stimulate local immune responses pivotal for combating disease at the site of pathology.

Strategic Positioning in the Biopharmaceutical Landscape

Synlogic occupies a unique position within the competitive biopharmaceutical industry. The company’s approach stands out for its integration of advanced synthetic biology techniques and microbiome research, positioning it at the forefront of a transformative shift in drug development. Unlike traditional small-molecule drugs, Synlogic’s therapeutics are designed as living medicines that operate in a highly specific and controlled manner to address underlying biological deficiencies. This methodology has garnered attention for its potential to offer novel treatment modalities where conventional therapies have limited success.

Innovation in Synthetic Biotics

The hallmark of Synlogic’s innovation lies in its proprietary approach to designing synthetic biotics. By employing precise genetic modifications, the engineered probiotics are tailored to exhibit a targeted therapeutic function, such as the remediation of enzymatic deficiencies or modulation of immune effectors at localized disease sites. This biotechnological breakthrough not only optimizes the delivery of therapeutic agents through oral administration but also minimizes systemic exposure, thereby enhancing safety and tolerability.

Operational Excellence and Research Focus

Grounded in robust research and development, Synlogic’s operations embody a commitment to scientific excellence and innovation. The company emphasizes a research-driven model where iterative preclinical studies and clinical validations are paramount to translating complex scientific insights into viable therapeutics. The scientific rationale behind its synthetic biotics is underpinned by rigorous engineering processes and the utilization of advanced genetic techniques to ensure that each therapeutic candidate meets high standards of quality and efficacy.

Value Proposition and Market Impact

By offering an alternative therapeutic modality through engineered probiotics, Synlogic enhances the treatment landscape for patients suffering from rare metabolic conditions and associated disorders. The company's non-invasive, oral delivery system represents a significant advancement in patient care by simplifying drug administration and potentially reducing associated healthcare burdens. Synlogic's scientific approach not only diversifies the biopharmaceutical market but also establishes a foundation for future research into microbiome-related therapies.

Comprehensive Therapeutic Portfolio

The company’s evolving pipeline encompasses therapeutics specifically designed for treating enteric hyperoxaluria, gout, cystinuria, and other disorders. Each candidate is developed with a focus on achieving high specificity for the targeted pathway, ensuring that therapeutic interventions are both effective and safe. This comprehensive strategy reflects Synlogic’s commitment to addressing unmet medical needs through the application of cutting-edge synthetic biology techniques.

Risk Management and Development Considerations

Recognizing the complexities inherently associated with the development of innovative therapeutics, Synlogic adopts stringent protocols in both early-stage research and later-stage clinical validation. The reversible and non-colonizing nature of its synthetic biotics mitigates potential risks, ensuring that the therapeutic effects can be controlled and monitored with precision. The company has embedded comprehensive safety metrics within its drug development process, thus reinforcing its commitment to patient safety and scientific integrity.

Conclusion

In summary, Synlogic exemplifies a forward-thinking approach in the biopharmaceutical space by harnessing the power of synthetic biology to develop innovative, microbiome-based therapies. Its emphasis on engineered probiotics, meticulous research, and targeted therapeutic design positions the company as a notable contributor to the field of rare metabolic disorder treatment. With a balanced focus on scientific rigor and practical application, Synlogic continues to push the boundaries of what is possible in modern drug development, offering novel therapeutic opportunities for severe and otherwise difficult-to-treat diseases.

  • Key Differentiators: Integration of synthetic biology with microbiome science.
  • Technological Focus: Engineered, non-colonizing, GI-restricted therapeutics.
  • Therapeutic Areas: Rare metabolic disorders, immune modulation, and metabolic dysfunctions.
  • Delivery Mechanism: Oral administration ensuring patient-friendly and scalable use.
  • Research-Driven Model: Emphasis on robust preclinical studies and clinical validations.

This detailed overview provides a comprehensive and informative view of Synlogic, its business model, and its scientific innovations that are reshaping how metabolic and rare diseases may be treated. The explanation is designed to serve investors, industry analysts, and those with an interest in the continued evolution of biopharmaceutical technologies.

Rhea-AI Summary

Synlogic (SYBX) announced the pricing of an underwritten public offering, selling 10 million shares at $3.00 each, aiming for gross proceeds of $30 million. The offering will close around April 20, 2021, pending usual conditions. An additional 1.5 million shares may be purchased at the same price by the underwriter. The offering is conducted under a shelf registration statement effective since August 2018. The funds raised will support Synlogic's innovative Synthetic Biotic medicines targeting metabolic disorders, including Phenylketonuria and Enteric Hyperoxaluria.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.59%
Tags
-
Rhea-AI Summary

Synlogic (Nasdaq: SYBX), based in Cambridge, Massachusetts, has commenced an underwritten public offering of its common stock as of April 15, 2021. All shares will be offered by the company, with a possibility for the underwriter to purchase an additional 15% of the shares within 30 days. The offering is contingent on market conditions, and specifics regarding size and terms are not guaranteed. The prospectus will be available on the SEC's website. Synlogic focuses on synthetic biology aimed at treating metabolic disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.59%
Tags
-
Rhea-AI Summary

Synlogic, Inc. (Nasdaq: SYBX) presented Phase 1 study data for SYNB1618, an oral treatment for Phenylketonuria (PKU), during the ACMG annual meeting. The results reveal that the solid oral formulation is well tolerated and metabolically active, effectively reducing plasma D5-Phe levels in healthy volunteers. This data supports further clinical development, with a Phase 2 trial, SynPheny, targeting adults with PKU expected to yield results in late 2021. PKU is a serious genetic disorder that requires early intervention to prevent neurological damage.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
none
Rhea-AI Summary

Synlogic, Inc. (Nasdaq: SYBX) presented data on its investigational drug SYNB1891 for treating solid tumors and lymphoma at the AACR annual meeting. The ongoing Phase 1 clinical trial demonstrated that SYNB1891 is safe and well-tolerated, with no dose-limiting toxicities reported. It showed target engagement through dose-dependent increases in serum cytokines and evidence of durable stable disease in two patients. The company is advancing the drug through further dose escalation and plans to report combination therapy data by the end of 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Synlogic, Inc. (Nasdaq: SYBX) announced participation in virtual conferences, including the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021 and the Jefferies Microbiome-based Therapeutics Summit on April 22, 2021. CEO Aoife Brennan and Daniel Rosan will present at the Needham conference, while Brennan will engage in a Fireside Chat at the Jefferies Summit. These events aim to showcase Synlogic's synthetic biology platform and pipeline targeting metabolic disorders and immunology. Webcasts will be available on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
conferences
-
Rhea-AI Summary

Synlogic, Inc. (SYBX) reported its 2020 financial results, revealing a consolidated net loss of $59.2 million, or $1.65 per share, compared to a net loss of $51.4 million in 2019. The company had no revenue in Q4 2020, down from $1.2 million in Q4 2019. However, significant advancements were noted in its clinical programs for Phenylketonuria (PKU) and Enteric Hyperoxaluria, with positive proof-of-mechanism data in humans. Synlogic anticipates important clinical readouts later this year and projected sufficient cash to fund operations into 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
Rhea-AI Summary

Synlogic, Inc. (Nasdaq: SYBX) announced that SYNB8802 achieved proof of mechanism in its Dietary Hyperoxaluria study, demonstrating a 28.6% reduction in urinary oxalate levels compared to placebo. The treatment was well-tolerated in healthy volunteers, leading to the initiation of Part B, which will evaluate SYNB8802 in patients post-Roux-en-Y gastric bypass surgery. Data is expected in the second half of 2021. SYNB8802 aims to provide treatment for Enteric Hyperoxaluria, a condition with no approved therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
-
Rhea-AI Summary

Synlogic, Inc. (NASDAQ: SYBX) announced it will release its fourth quarter and full year 2020 financial results on March 25, 2021, before market opening. A conference call will follow at 8:30 am ET, featuring a review of financial outcomes and corporate updates. Domestic callers can dial (844) 815-2882, while international callers should use (213) 660-0926, with conference ID 4897219. The call will be accessible via webcast on the Synlogic website, with a replay available for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Synlogic, Inc. (Nasdaq: SYBX) announced the promotion of Dr. Caroline Kurtz to Chief Development Officer, overseeing portfolio strategy and the advancement of its Synthetic Biotic medicines, including SYNB1618 and SYNB8802. With 25 years of experience, Dr. Kurtz aims to drive clinical progress. Additionally, Daniel Rosan was promoted to Senior Vice President and Head of Finance, while Dr. Jamie Austin assumed leadership in Regulatory Affairs. The company focuses on metabolic disorders and looks to leverage its synthetic biology platform for therapeutic development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.62%
Tags
management
Rhea-AI Summary

On February 15, 2021, Synlogic (Nasdaq: SYBX) announced upcoming presentations by CEO Aoife Brennan and the executive team at several virtual banking and industry conferences. Key events include the BIO CEO & Investor Digital Conference on February 16, Cantor Fitzgerald Industry Panel on February 18, and the SVB Leerink Global Healthcare Conference on February 25. Synlogic focuses on synthetic biology to create medicines for metabolic disorders and other diseases. Archived webcasts will be available on their website for 30 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the current stock price of Synlogic (SYBX)?

The current stock price of Synlogic (SYBX) is $1.22 as of April 1, 2025.

What is the market cap of Synlogic (SYBX)?

The market cap of Synlogic (SYBX) is approximately 14.0M.

What does Synlogic specialize in?

Synlogic specializes in developing innovative therapeutics using synthetic biotics. The company focuses on engineering probiotics to address rare metabolic disorders and other serious diseases.

How does Synlogic's synthetic biotics platform work?

The platform involves genetically engineering well-characterized probiotic bacteria to perform targeted therapeutic functions. These engineered microbes are designed to be delivered orally and act primarily within the gut microbiome.

Which disease areas are the main focus for Synlogic?

Synlogic primarily targets rare metabolic conditions such as phenylketonuria and homocystinuria, while also exploring therapeutics for conditions like enteric hyperoxaluria, gout, and cystinuria.

What advantages do Synlogic's therapeutics offer over traditional drugs?

Synlogic's therapeutics offer a non-colonizing, reversible, and GI-restricted drug delivery method via oral administration, which simplifies treatment management and enhances patient safety.

How does Synlogic ensure the safety of its engineered probiotics?

Safety is ensured by using a well-characterized strain of Escherichia coli and employing meticulous genetic engineering techniques. The specificity, non-colonizing nature, and reversibility of its synthetic biotics are all key components of its safety profile.

What differentiates Synlogic in the competitive biopharmaceutical market?

Synlogic differentiates itself through the integration of synthetic biology with advanced microbiome research. Its unique therapeutic approach and focus on rare metabolic disorders set it apart from traditional drug development models.

How is Synlogic positioned within the synthetic biology and microbiome sectors?

Synlogic is positioned as an innovative entity at the intersection of synthetic biology and microbiome therapeutics. Its research-driven model and proprietary platform highlight its expertise in developing next-generation, microbiome-based treatments.

What is the significance of oral administration in Synlogic's therapeutic approach?

Oral administration is significant because it enables a patient-friendly delivery system that is both scalable and practical. This approach also minimizes systemic exposure, ensuring that therapeutic effects are targeted and controlled.
Synlogic

Nasdaq:SYBX

SYBX Rankings

SYBX Stock Data

14.04M
10.32M
11.79%
64.61%
0.44%
Biotechnology
Pharmaceutical Preparations
Link
United States
WINCHESTER